Endovascular treatment of post-thrombotic syndrome using nitinol venous stents is associated with symptomatic improvement, but ~40% require re-intervention. We examined whether ultrasound surveillance was sensitive for re-intervention, and whether it was possible to predict patients at greatest risk of re-intervention.
Use of catheter-directed thrombolysis (CDT) for the treatment of acute iliofemoral deep vein thrombosis, may reduce the incidence of post-thrombotic syndrome, but carries the risk of major haemorrhage. We aim to assess whether addition of pharmacomechanical AngioJet thrombectomy, can minimise exposure to potentially dangerous lytic agents, while maintaining a beneficial patient outcome.
Methods:
A retrospective analysis of all cases of acute ilio-femoral DVT presenting to a tertiary centre between 2011 and 2017. Outcome measures included lysis duration, dose of lytic therapy, complication rate, incidence of post-thrombotic syndrome, and venous patency.
Results:
81 patients were treated with CDT versus 70 with AngioJet thrombectomy. A decrease in lysis duration, (40hrs (95%CI:34-46) vs. 53hrs (95%CI:49-58) p=0.0001)) and in lytic dose vs. 57mg (95%CI:52-61) p=0.007)) were observed with use of AngioJet. Reduction was greatest for cases initially treated with Power Pulse TM AngioJet thrombectomy ) and 42 mg (95%CI:34-50)(n=24)). Incidence of haemoglobinuria was increased following AngioJet thrombectomy (18.6% v. 3.7%). One major bleed was observed following CDT. Villalta scores at 6mths and 1yr, were comparable (p=0.28). Primary-assisted and secondary patency was greater amongst patients initially treated with AngioJet versus CDT alone (n=64,p=0.029). Use of Power Pulse TM AngioJet thrombectomy did not confer an advantage when used following 48hrs of unsuccessful CDT (n=10, p=0.001).
Conclusion:
Early use of adjuvant AngioJet thrombectomy can reduce overall dose and exposure to lysis during treatment of iliofemoral DVT, without compromise to patient outcome.
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Diabetic foot disease is a condition with increasing worldwide prevalence. Diabetes mellitus (DM) affects the regulation of vascular tone and response to trauma of the skins microcirculation, increasing the risk of ulceration. How microcirculatory function changes following percutaneous angioplasty (PA) and during ulcer healing is poorly understood. This pilot study aims to examine this.
Patients with DM and active foot ulceration were recruited from diabetic foot clinics into one of two cohorts. Group One (G1) had significant peripheral arterial disease (PAD) requiring PA and group Two (G2) had no significant PAD. At recruitment and prior to the procedure the patients pedal microcirculation was examined using laser Doppler fluxmetry. The main parameter examined was time to maximum flux (TtM) following a three-minute occlusion of the affected limb. These measurements were repeated monthly until the ulcer healed.
Nine patients were recruited to G1 and fourteen to G2. Six patients had healed by the end of the study in both groups. In G1, there was a reduction in the TtM following PA. At last visit, on the study toe, TtM had significantly reduced from 210.5s (72.18-231) to 50.71s (27.38-105.18, p=0.046) in those who healed. In G2, on both the study toe and dorsum, there was an increase in TtM (study toe, 13.40s (6.33-73.85) to 64.43 (22.05-114.20) , p=0.028).
PA appears to be related to significant improvement in microvascular reactivity. The increase in TtM in patients without PAD may be related to a reduction in inflammation following healing. A higher powered study is required.
